23andMe Investor Presentation Deck
April 2023, 57 slides
  1. 23andMe
  2. Related Decks
  3. Investor Presentation Decks
investor presentation | 23andMe
disclaimer | 23andMe
mission to help people access understand and benefit from the human genome | 23andMe
impact of different factors on risk of premature death the problem today system has only a small impact on our health and well being death | 23andMe
today system is was more personalized | 23andMe
revolutionizing the diagnosis prevention and treatment of human disease | 23andMe
unlocking the genetic code creates the opportunity to revolutionize the diagnosis prevention and treatment of human disease a is a data problem a very big data problem billion | 23andMe
consumer scale and empowerment is the key to disrupting | 23andMe
the size and scale of enables rapid novel discoveries welcome to you | 23andMe
we pioneered digital to empower customers with affordable direct access gee | 23andMe
providing customers with key actionable insights | 23andMe
genetic data helps drive behavior change | 23andMe
opportunity for personalized at scale | 23andMe
transforming with genetic health services at scale | 23andMe
problems we are solving | 23andMe
what are genetic health services health predispositions wellness aly in | 23andMe
future of fully integrated genetic health services states | 23andMe
first step genetic health evaluation genetic health evaluation valuation | 23andMe
next step implementing a genetically informed personalized health wellness plan | 23andMe
personal genome service grain | 23andMe
unique to authorized reports cyp | 23andMe
long term engagement with customers | 23andMe
bold predictions for human by the regular use of genomic information will have transitioned from to in all clinical settings making genomic testing as routine as complete blood counts | 23andMe
transforming the development of therapeutics with the | 23andMe
opportunities to collaborate with | 23andMe
an experienced leadership team | 23andMe
therapeutics core capabilities | 23andMe
potential to use genetics to more efficiently develop novel therapeutics by power need and speed drug development is inefficient time to | 23andMe
| 23andMe
genome wide association studies | 23andMe
size and scale accelerate target discovery | 23andMe
hundreds of distinct clinical phenotypes across major and rare diseases a | 23andMe
genetic association of the signalling pathway with asthma a | 23andMe
breadth of provides genetic understanding beyond single diseases a eczema | 23andMe
a research and development pipeline covering multiple therapeutic areas | 23andMe
systematic scalable research platform yields novel drug targets | 23andMe
oncology i programs | 23andMe
our i programs were identified with and applied to our proprietary i genetic signature | 23andMe
me targeting | 23andMe
was identified as a promising anti cancer drug target with proprietary oncology i genetic signature | 23andMe
is an immune | 23andMe
me me binds with high affinity to and inhibits signaling me | 23andMe
is expressed on tumor infiltrating lymphocytes from the cancer genome atlas | 23andMe
inhibition of has the potential to address resistance to anti therapies anti | 23andMe
phase a study of me in patients with locally advanced or metastatic solid malignancies | 23andMe
me targeting a genetically validated approach to anti cancer therapy | 23andMe
targeting | 23andMe
the program is a prime example of the value brings to drug discovery and development | 23andMe
| 23andMe
investing in future growth in a fiscally responsible manner | 23andMe
revenue composition | 23andMe
consumer services revenue seasonality by fiscal quarter | 23andMe
research and development expense | 23andMe
sales and marketing expense composition | 23andMe
appendix | 23andMe
the vast majority of discoveries can be made without large scale sequencing | 23andMe
value proposition | 23andMe
See More
23andMe
Investor Presentation Decks
Diagnostics & Research Decks
Healthcare Decks
Explore Topics
Cancer
Wellness
Drug discovery
Drug development
Rare disease
Recent decks by 23andMe
Investor Presentation
January 2024
Investor Presentation
August 2022
Investor Presentation
February 2022
Investor Day
January 2022
See all presentations by 23andMe (7 decks)
Related decks
AstraZeneca
Results
July 2023
Exscientia
Results
May 2022
AstraZeneca
Results
July 2021
ATAI
Investor Presentation
June 2020
Exscientia
Investor Day
January 2024
Exscientia
Investor Presentation
June 2022
AstraZeneca
Investor Presentation
March 2022
AbCellera
Investor Conference
September 2021
Recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
January 2024
Investor Presentation
August 2022
Investor Presentation
February 2022
Investor Day
January 2022
AstraZeneca
Results
July 2023
Exscientia
Results
May 2022
AstraZeneca
Results
July 2021
ATAI
Investor Presentation
June 2020
Exscientia
Investor Day
January 2024
Exscientia
Investor Presentation
June 2022
AstraZeneca
Investor Presentation
March 2022
AbCellera
Investor Conference
September 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io